Stem cell-derived pancreatic islets are being studied as a rich transplantable source for insulin production, a therapeutic ...

TUCSON, AZ / ACCESS Newswire / April 29, 2025 / Retatrutide, also known as LY3437943, is an innovative triple receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), ...

Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical ...